Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

BACKGROUND: The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine candidates. We aimed to assess the safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate, BBIBP-CorV, in humans. METHODS: We did a randomised, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Shengli, Zhang, Yuntao, Wang, Yanxia, Wang, Hui, Yang, Yunkai, Gao, George Fu, Tan, Wenjie, Wu, Guizhen, Xu, Miao, Lou, Zhiyong, Huang, Weijin, Xu, Wenbo, Huang, Baoying, Wang, Huijuan, Wang, Wei, Zhang, Wei, Li, Na, Xie, Zhiqiang, Ding, Ling, You, Wangyang, Zhao, Yuxiu, Yang, Xuqin, Liu, Yang, Wang, Qian, Huang, Lili, Yang, Yongli, Xu, Guangxue, Luo, Bojian, Wang, Wenling, Liu, Peipei, Guo, Wanshen, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561304/
https://www.ncbi.nlm.nih.gov/pubmed/33069281
http://dx.doi.org/10.1016/S1473-3099(20)30831-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561304/
https://www.ncbi.nlm.nih.gov/pubmed/33069281
http://dx.doi.org/10.1016/S1473-3099(20)30831-8

Ejemplares similares